TD Asset Management Inc. lifted its holdings in Pfizer Inc. (NYSE:PFE) by 1.5% during the 4th quarter, Holdings Channel reports. The firm owned 8,723,552 shares of the biopharmaceutical company’s stock after acquiring an additional 129,557 shares during the quarter. Pfizer makes up about 0.7% of TD Asset Management Inc.’s portfolio, making the stock its 26th biggest holding. TD Asset Management Inc.’s holdings in Pfizer were worth $380,783,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in PFE. Vanguard Group Inc grew its stake in shares of Pfizer by 1.5% in the 3rd quarter. Vanguard Group Inc now owns 441,792,969 shares of the biopharmaceutical company’s stock worth $19,469,816,000 after purchasing an additional 6,620,749 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Pfizer by 1.5% in the third quarter. Vanguard Group Inc. now owns 441,792,969 shares of the biopharmaceutical company’s stock worth $19,469,816,000 after acquiring an additional 6,620,749 shares in the last quarter. Bessemer Group Inc. increased its position in shares of Pfizer by 3,845.7% in the third quarter. Bessemer Group Inc. now owns 6,366,640 shares of the biopharmaceutical company’s stock worth $280,580,000 after acquiring an additional 6,205,282 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Pfizer by 3.7% in the third quarter. Bank of New York Mellon Corp now owns 70,231,649 shares of the biopharmaceutical company’s stock worth $3,095,110,000 after acquiring an additional 2,497,736 shares in the last quarter. Finally, Canada Pension Plan Investment Board increased its position in shares of Pfizer by 40.3% in the third quarter. Canada Pension Plan Investment Board now owns 7,552,926 shares of the biopharmaceutical company’s stock worth $332,857,000 after acquiring an additional 2,171,400 shares in the last quarter. 69.17% of the stock is currently owned by institutional investors.

PFE traded up $0.09 on Wednesday, reaching $41.77. 4,486,004 shares of the company traded hands, compared to its average volume of 24,391,082. Pfizer Inc. has a 52-week low of $35.32 and a 52-week high of $46.47. The company has a market capitalization of $246.87 billion, a PE ratio of 13.92, a PEG ratio of 2.40 and a beta of 0.71. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.27 and a current ratio of 1.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 30th. The biopharmaceutical company reported $0.85 EPS for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.10. Pfizer had a net margin of 21.31% and a return on equity of 27.48%. The firm had revenue of $13.12 billion for the quarter, compared to the consensus estimate of $13.01 billion. During the same period in the previous year, the firm posted $0.77 earnings per share. The firm’s revenue was up 1.6% on a year-over-year basis. On average, equities analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 10th will be given a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a yield of 3.45%. The ex-dividend date is Thursday, May 9th. Pfizer’s payout ratio is presently 48.00%.

In other news, EVP Dawn Rogers sold 15,002 shares of the business’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $42.98, for a total value of $644,785.96. Following the completion of the sale, the executive vice president now directly owns 28,722 shares in the company, valued at $1,234,471.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Mikael Dolsten sold 100,471 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $43.56, for a total transaction of $4,376,516.76. Following the completion of the sale, the insider now owns 390,097 shares of the company’s stock, valued at $16,992,625.32. The disclosure for this sale can be found here. Insiders have sold 288,726 shares of company stock worth $12,534,617 over the last ninety days. 0.09% of the stock is currently owned by insiders.

PFE has been the topic of several analyst reports. Credit Suisse Group raised shares of Pfizer from a “neutral” rating to an “outperform” rating in a research report on Thursday, January 31st. Zacks Investment Research downgraded shares of Pfizer from a “hold” rating to a “sell” rating in a research report on Thursday, March 28th. Cantor Fitzgerald reissued a “buy” rating and issued a $53.00 target price on shares of Pfizer in a research report on Tuesday, February 19th. Citigroup reissued a “neutral” rating and issued a $41.00 target price on shares of Pfizer in a research report on Wednesday, February 20th. Finally, UBS Group downgraded shares of Pfizer from a “buy” rating to a “neutral” rating in a research report on Wednesday, January 23rd. Fourteen investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Pfizer has an average rating of “Hold” and a consensus price target of $45.83.

TRADEMARK VIOLATION WARNING: This piece was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://theolympiareport.com/2019/05/22/pfizer-inc-pfe-holdings-increased-by-td-asset-management-inc.html.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: Understanding Specialty Certificates of Deposit

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.